head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2025, vol. 31, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2025311.5985
Published online: 03 Febrary 2025

Case report
J of IMAB. 2025 Jan-Mar;31(1):5985-5988
REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION
Ivan TonevORCID logoCorresponding Autoremail, Chavdar BotevORCID logo, Georgui BalatzenkoORCID logo, Milcho MincheffORCID logo,
National Specialized Hospital for Active Treatment of Hematological Diseases- Sofia, Bulgaria.

ABSTRACT:
Objective: Chronic myelogenous leukemia (CML)  is a disease, that in cases with high leukocyte numbers, is treated with hydration and cytoreductive therapy.
Materials and Methods:A 20-year-old female patient, during a routine examination for pregnancy, presented with elevated white blood cells (WBC) count (over 275x109/L) and splenomegaly without any complaints. The diagnosis of Ph-positive CML was confirmed by cytology and PCR [presence of p210 type BCR::ABL1 [e13a2 (b2a2)] transcripts. Since she was in her 6th month of pregnancy, abortion or conventional treatment (tyrosine kinase inhibitors (TKI), chemotherapy and/or allogeneic haematopoietic stem cell transplant) were contraindicated due to the high risk for both the mother and the fetus. The patient was treated with two consecutive leukaphereses followed by weekly apheresis for about 3,5 months until the day of the delivery. Each procedure included the processing of 1000-1200 ml of whole blood with the separation of around 600 ml white blood cell concentrate and plasma.
Results:The patient's WBC count was kept between 170 and 270 x 109/L until childbirth, and immediately after delivery, imatinib mesylate therapy was initiated.A healthy male child with a weight of 2250 kg and height of 46 сm was born. The mother achieved hematologic, cytogenetic and molecular remission within the next 6-9 months after initiation of tyrosine kinase inhibitor therapy.
Discussion:
The classical treatment for CML includes tyrosine kinase inhibitors, chemotherapy and/or allogeneic haematopoietic stem cell transplantation. All of these approaches have teratogenic potential, and therapeutic schemes should involve contraception. In cases with existing advanced pregnancy, therapeutic leukapheresis is a valid option for controlling WBC counts until the delivery date. Despite the later initiation of TKI therapy, the deep molecular response is still present thirteen years after the initiation of therapy.

Keywords: Chronic myelogenous leukemia, cytapheresis, TKI, imatinib, CML, pregnancy,

pdf - Download FULL TEXT /PDF 1072 KB/
Please cite this article as: Tonev I, Botev C, Balatzenko G, Mincheff M. Repeated therapeutic leukapheresis - a sole treatment during pregnancy as a bridge before tyrosine kinase inhibitors for a pregnant woman with chronic myelogenous leukemia – a case report and discussion. J of IMAB. 2025 Jan-Mar;31(1):5985-5988. [Crossref - 10.5272/jimab.2025311.5985]

Corresponding AutorCorrespondence to: Ivan Tonev, National Specialized Hospital for Active Treatment of Hematological Diseases- Sofia; 1A, Kliment Ohridski Blvd., 1797 Sofia, Bulgaria; E-mail: i.tonev@hematology.bg

REFERENCES:
1. Liesveld JL, Lichtman MA. Chapter 88: Chronic Myelogenous Leukemia and Related Disorders. In: Williams Hematology. 10e.Editors: Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DC. McGraw Hill. 2021. [Internet]
2.  Kantarjian H, Jabbour E, Cortes J. Chapter 105: Chronic myeloid leukemia. In: Harrison's Principles of Internal Medicine. 21st Edition. McGraw Hill Education. 2022. 2800p. [Internet]
3. Lisichkov T. [Therapeutic hemapheresis.] In: Clinical hematology. Part 1. Editors Lisichkov T, Meshkov T. Sofia. 2004. 572-579. [in Bulgarian]
4. >Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol. 2009 Sep;22(3):455-74. [PubMed ]
5. Choudhary DR, Mishra P, Kumar R, Mahapatra M, Choudhry VP. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol. 2006 Jan;17(1):178-9. [PubMed]
6. McLeod BC. Therapeutic Apheresis: A Physician's Handbook. S. Karger AG. 1 .01. 2005. 200p. [Internet]
7. Strobl FJ, Voelkerding KV, Smith EP. Management of chronic myeloid leukemia during pregnancy with leukapheresis. J Clin Apher. 1999; 14(1):42-4. [PubMed]
8. Ali R, Ozkalemkaş F, Ozkocaman V, Ozçelik T, Ozan U, Kimya Y, et al. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol. 2004 Apr;34(4):215-7. [PubMed]
9. Fitzgerald D, Rowe JM, Heal J.  Leukapheresis for control of chronic myelogenous leukemia during pregnancy. Am J Hematol. 1986 Jun;22(2):213-8. [PubMed]
10. Madabhavi I, Sarkar M, Modi M, Kadakol N. Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience. J Glob Oncol. 2019 Sep;5:1-11. [PubMed]

Received: 12 September 2024
Published online: 03 February 2025

back to Online Journal